Within the month of November 2017, NetScientific plc (LON:NSCI) portfolio companies had a series of announcements reflecting increased adoption of their products. ProAxsis announced increased sales of its research kits and guided to over £1m in sales in 2018. Wanda’s partner Health Resource Solutions announced that it would be expanding the deployment of the app to all of its applicable patients. Finally, Vortex announced the first commercial sale of its VTX-1 liquid biopsy platform.
ProAxsis: Research kit catching on
ProAxsis announced that it had tripled the number of orders for its Active Neutrophil Elastase Immunoassay (NEIA) kit in H217 over H117, partially as a result of a high number (75%) of repeat orders, and is on a run-rate to surpass £1m in sales in 2018. Outside of the near-term revenue, this is encouraging for both the adoption of further research kits and for the company’s point of care neutrophil elastase assay, NEATstik, which was CE marked in September 2017.
To read the entire report Please click on the pdf File Below: